Healthcare Industry News: VMS
News Release - September 20, 2012
Seattle Children's Hospital Acquires VentriPoint Heart Analysis SystemSEATTLE, WASHINGTON--(Healthcare Sales & Marketing Network) - VentriPoint Diagnostics (TSX VENTURE:VPT) (VPTDF) is pleased to announce the installation of its VMS™ heart analysis system at Seattle Children's Hospital, where it will be used to study a large variety of children with congenital and acquired heart disease. A special focus will be children with anemia (lack of red blood cells) who receive multiple blood donations and often have dilated hearts.
"The echocardiography laboratory at Seattle Children's Hospital is excited to work collaboratively with a local company, VentriPoint, to evaluate the performance of VMS™. In the clinical world, there is a need for objective, precise, and accurate assessments of right ventricular function. Traditionally, subjective measures of function have been used," stated Brian Soriano, MD, FASE, Interim Director of the Echocardiography Laboratory, Seattle Children's Hospital, Assistant Professor of Pediatrics, Adjunct Assistant Professor of Radiology, University of Washington School of Medicine.
"Cardiac MRI, considered the reference standard for ventricular volumes, is costly, requires a large amount of time to obtain images, and may be accessible only on a limited basis in some hospitals. When compared to traditional echocardiographic methods, VMS™ has the potential to offer more accurate and precise ventricular volumes in a time-efficient manner," continued Dr. Soriano.
"Having a VMS™ installed in our home location will enable us to view first hand its use in a pediatric clinical setting in the United States,' said Dr. George Adams, CEO of VentriPoint. "In addition, we will be doing research to look at expanding the VMS™ applications to include patients with acquired heart conditions."
The VMS™ is for investigational use only in the United States and is approved for clinical use in Canada and Europe.
About Seattle Children's Hospital
Consistently ranked as one of the best children's hospitals in the country by U.S. News & World Report, Children's serves as the pediatric and adolescent academic medical referral center for the largest landmass of any children's hospital in the country (Washington, Alaska, Montana and Idaho). For more than 100 years, Children's has been delivering superior patient care and advancing new treatments through pediatric research. Children's serves as the primary teaching, clinical and research site for the Department of Pediatrics at the University of Washington School of Medicine. The hospital works in partnership with Seattle Children's Research Institute and Seattle Children's Hospital Foundation. For more information, visit http://www.seattlechildrens.org.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS™ diagnostic tool and is pursuing the US-FDA approval through the 510(k) process.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Source: VentriPoint Diagnostics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.